Physician profile
Jonathan Tye
NPI 1417057068
$12,761.20
in general payments reported to CMS, 2019-2025
30 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,491 · 2020: $921 · 2021: $2,465 · 2022: $2,440 · 2023: $2,153 · 2024: $2,105 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,424 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,423.81 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,835.44 | 2019-2025 | Aveir, Pressurewire, Coroflow |
| Novartis Pharmaceuticals Corporation | $1,775.27 | 2019-2025 | |
| Boston Scientific Corporation | $1,012.51 | 2019-2024 | Emerge Push, Watchman Access System, Watchman Flx |
| Abiomed | $978.24 | 2021-2025 | Impella |
| Medtronic, INC. | $933.60 | 2021-2024 | Onyx Frontier, Corevalve Evolut R, Micra |
| Astrazeneca Pharmaceuticals Lp | $800.47 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $734.14 | 2019-2025 | Camzyos, Eliquis |
| Shockwave Medical, INC | $611.64 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $446.87 | 2021-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $437.18 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $433.82 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $399.33 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $375.15 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $367.78 | 2019-2022 | |
| Edwards Lifesciences Corporation | $353.39 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $290.78 | 2019-2024 | Lifevest |
| Cvrx, INC. | $201.23 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $126.09 | 2023-2024 | Inpefa |
| Amgen INC. | $116.24 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $96.31 | 2024 | (Bq9) Coronary Ivus |
| Ethicon US, LLC | $57.03 | 2025 | Vistaseal, Surgiflo Hemostatic Matrix, Stratafix |
| Kiniksa Pharmaceuticals, Ltd. | $52.38 | 2021-2023 | Arcalyst |
| Chiesi USA, INC. | $50.99 | 2022-2025 | Kengreal |
| Esperion Therapeutics, INC. | $48.40 | 2021 | |
| Pfizer INC. | $47.65 | 2019-2020 | |
| Teleflex LLC | $47.04 | 2019 | |
| Sanofi-Aventis U.S. LLC | $45.83 | 2019-2021 | |
| Glaxosmithkline, LLC. | $35.13 | 2025 | Arexvy, Shingrix |
| Stryker Corporation | $26.45 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kiniksa Pharmaceuticals International, Plc | $24.82 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Tye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.